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To evaluate the relationship between circulating adiponectin and insulin sensitivity in patients with hyperthyroid Graves’ disease,
we studied 19 adult patients with this disease and 19 age- and sex-matched euthyroid controls. All hyperthyroid patients
were treated with antithyroid drugs and were re-evaluated after thyroid function normalized. Before antithyroid treatment, the
adiponectin plasma concentrations were not diﬀerent comparing with those in control group. The adiponectin levels remained
unchangedaftertreatment.Thehomeostasismodelassessmentofinsulinresistance(HOMA-IR)inhyperthyroidgroupwashigher
beforetreatmentthanaftertreatment.Therewasnosigniﬁcantdiﬀerenceinserumglucoseandinsulinlevelsbetweenhyperthyroid
and control groups and in the hyperthyroid group before and after treatment. BMI-adjusted adiponectin levels were not diﬀerent
among three groups. On the other hand, BMI-adjusted insulin levels and HOMA-IR values were signiﬁcantly decreased after
management of hyperthyroidism. Pearson’s correlation revealed that insulin and HOMA-IR values positively correlated with
triiodothyronine (T3) and free thyroxine (FT4) levels. However, adiponectin did not correlate with T3, FT4, insulin, HOMA-
IR and thyrotropin receptor autoantibody (TRAb) levels. In conclusion, insulin resistance associated with hyperthyroidism is not
mediated by the levels of plasma adiponectin.
1.Introduction
Hyperthyroidism has been linked to reduced lean and fat
body mass, resulting in lower-than-normal body weight.
Patients with hyperthyroidism often have disrupted inter-
mediary metabolism and thyrotoxicosis which has been
associated with insulin resistance [1–3]. The mechanism of
insulin resistance induced by thyrotoxicosis has not been
completely elucidated. Adipocytokines which are regulated
by thyroid hormones may play a role in the development of
insulin resistance in hyperthyroidism.
Adipocytokines play crucial roles in the regulation of
energy homeostasis, insulin sensitivity, lipid/carbohydrate
metabolism, and even inﬂammatory/atherogenic reactions
[4–11]. Among the adipocytokines, adiponectin is the
only one to have anti-inﬂammatory and antiatherogenic
properties [6–9]. It is paradoxically decreased in an
insulin-resistance state [4]. We, therefore, measured plasma
adiponectinconcentrationsinsubjectswithhyperthyroidism
due to Graves’ disease before and after antithyroid treat-
ment and in euthyroid control subjects. The relationships
amongadiponectin,insulinconcentrations,andhomeostatic
model assessment-insulin resistance index (HOMA-IR) were
evaluated. We aimed to evaluate if adiponectin would be
associated with the indicator of insulin resistance in patients
with hyperthyroid Graves’ disease.
2. Methods
2.1. Subjects. The study enrolled 19 patients with hyperthy-
roidism due to Graves’ disease (14 women and 5 men) and2 Journal of Thyroid Research
Table 1: Characteristics of control subjects and hyperthyroid subjects before and after treatment.
Control (n = 19) Hyperthyroid (n = 19)
Pretreatment Posttreatment
Age (years) 36.7 ± 2.7 32.6 ± 1.8 —
Sex (F/M) 17/2 14/5 —
Postmenopause 3/17 2/14 —
Body Weight (kg) 55.4 ± 1.9 53.9 ± 1.8 55.6 ± 2.0
BMI (kg/m2)∗ 22.9 ± 0.8 20.6 ± 0.5 21.1 ± 0.6
Free T4 (ng/dL)∗ 1.35 ± 0.05 5.22 ± 0.53 1.14 ± 0.09
T3 (ng/dL)∗ 113.1 ± 5.3 476.0 ± 46.9 115.6 ± 8.0
TSH (µIU/mL)∗ 1.32 ± 0.05 0.02 ± 0.00 3.47 ± 1.65
Glucose (mmol/L) 4.93 ± 0.10 5.14 ± 0.08 4.79 ± 0.12
Adiponectin (ng/L) 6.55 ± 0.71 5.57 ± 0.97 6.62 ± 0.80
Insulin (µIU/mL) 7.80 ± 1.06 8.86 ± 1.02 5.66 ± 0.69
HOMA-IR (mM mU/L)∗ 1.71 ± 0.23 2.06 ± 0.26 1.21 ± 0.16
TRAb (%)∗ — 44.9 ± 5.7 29.1 ± 5.0
Data are mean ± SEM. Comparisons among three groups were made by one-way analysis of variance. ∗P<. 05. Post-hoc test by Bonferroni; HOMA-IR:
pretreatment versus posttreatment, P = .027; control versus pre- or posttreatment, P = ns.
19 age- and sex-matched euthyroid controls (17 women and
2 men) as previous study mentioned [12]. All hyperthyroid
patients were treated with antithyroid drugs, either propy-
lthiouracil (procil, Nysco Co., Ltd., Taiwan) or carbimazole
(neo-thyreostat, Dr. Herbrand Co., Ltd., Germany). Thyroid
function was normalized after three to seven months of
treatment by antithyroid drugs (mean = 5.4 ± 0.4 months).
The patients were evaluated at the time of diagnosis and after
thyroid function normalized.
The plasma and serum samples were tested to measure
serum concentrations of free thyroxine (FT4), total tri-
iodothyronine (T3), thyrotropin (TSH), thyrotropin recep-
tor autoantibody (TRAb), glucose, insulin, and plasma con-
centrations of adiponectin (the plasma assays of adiponectin
had been performed simultaneously with the former proto-
col and not reported), all after overnight fasting. Body mass
index (BMI) was calculated as weight in kilograms divided
by the square of the height in meters. Insulin resistance
was estimated by using the HOMA-IR index, calculated as
serum glucose concentration (mmol/L) × serum insulin
concentration (mU/L)/22.5.
2.2. Biochemistry and Hormone Analyses. Serum glucose,
FT4, T3, TSH, and insulin concentrations were measured as
former protocol reported [12]. Plasma adiponectin concen-
trations were measured by the quantitative sandwich enzyme
immunoassay technique (R & D systems, Inc., Minneapolis,
MN, USA). The intraassay and inter-assay CVs were 3.4%
and 5.8%, respectively. The sensitivity of the assay was
0.246ng/mL. Serum TRAb was analyzed by radioreceptor
assay method (RSR Ltd., Cardiﬀ CF23 8HE, UK). The levels
greater than 10% was considered positive.
2.3. Statistical Analyses. Data were reported as mean ±
standard error of the mean (SEM). Comparisons of hyper-
thyroidsubjectsbeforetreatment,hyperthyroidsubjectsafter
t r e a t m e n t ,a n de u t h y r o i dc o n t r o ls u b j e c t sw e r em a d eb y
usingone-wayanalysisofvariance(ANOVA)andBonferroni
test for post-hoc multiple comparisons. Mann-Whitney test
was used for nonparametric data. Correlations between
parameters were assessed by using Pearson’s correlation
analysis. A value of P<. 05 was considered as statistically
signiﬁcant.
3. Results
The demographic and clinical characteristics of the study
population are shown in Table 1.T h em e a n± SEM age was
32.6 ± 1.8 years for hyperthyroid subjects and 36.7 ± 2.7
years for matching control subjects. As expected, subjects
in the hyperthyroid group before treatment had lower TSH
and higher T3 and FT4 serum concentrations than they
did after treatment or the control group. In addition, TRAb
also decreased after antithyroid drugs treatment (44.9 ± 5.7
versus 29.1 ± 5.0%).
HOMA-IR values were higher in hyperthyroid group
before treatment (2.06 ± 0.26mM mU/L) than after treat-
ment (1.21 ± 0.16mM mU/L, P = .027). Before antithyroid
treatment, the adiponectin plasma concentrations were not
diﬀerent comparing with those in control group (5.57 ±
0.97 versus 6.55 ± 0.71ng/L, ns). The adiponectin levels
remained unchanged after treatment (6.62 ± 0.80 versus
5.57 ± 0.97ng/L, ns). There was no signiﬁcant diﬀerence in
serum glucose, and insulin levels between hyperthyroid and
control groups and in the hyperthyroid group before and
after treatment.Journal of Thyroid Research 3
Table 2: Comparisons of BMI-adjusted plasma adiponectin concentration, insulin concentration, and HOMA-IR value among the control
and hyperthyroid groups before and after treatment.
Control (n = 19) Hyperthyroid
Pretreatment (n = 19) Posttreatment (n = 19)
Adiponectin/BMI 0.30 ± 0.02 0.28 ± 0.05 0.32 ± 0.04
Insulin/BMI∗ 0.33 ± 0.04 0.43 ± 0.05 0.26 ± 0.03
HOMA-IR/BMI∗ 0.07 ± 0.01 0.10 ± 0.01 0.06 ± 0.01
Data are mean ± SEM. Comparisons among three groups were made by one-way analysis of variance. ∗P<. 05. Post-hoc test by Bonferroni; Insulin/BMI:
pretreatment versus posttreatment, P = .010. HOMA-IR/BMI: pretreatment versus posttreatment, P = .005.
Table 3: Pearson’s correlation coeﬃcients in patients with hyper-
thyroidism due to Graves’ disease.
Factors Adiponectin Insulin HOMA-IR
BMI −0.197 0.219 0.207
T3 −0.024 0.328∗ 0.364∗
FT4 0.141 0.405∗ 0.444∗∗
Adiponectin 1 −0.065 −0.095
Insulin −0.065 1 0.991∗∗
HOMA-IR −0.095 0.991∗∗ 1
TRAb 0.170 0.099 0.098
∗P<. 05, ∗∗P<. 01.
BMI-adjusted adiponectin levels were not diﬀerent
among three groups (Table 2). On the other hand, BMI-
adjusted insulin levels and HOMA-IR values were signiﬁ-
cantly decreased after management of hyperthyroidism.
Pearson’s correlation (Table 3) revealed that insulin and
HOMA-IR values were positively correlated with T3 and FT4
levels. However, adiponectin did not correlate with T3, FT4,
insulin, HOMA-IR, and TRAb levels.
4. Discussion
Patients with hyperthyroidism are known to have elevated
fastingserumglucoselevels[13,14],whichmaybeexplained
by increased endogenous glucose production through more
rapid glycogenolysis and gluconeogenesis [13, 15, 16]. The
speed of insulin-stimulated glucose disposal in peripheral
tissues is variable in hyperthyroidism and may be normal,
increased, or decreased [3].
Adipose tissue, an endocrine active tissue, releases
adipocytokines to modulate several peripheral tissue func-
tions. Among these adipocytokines, adiponectin is a 244
amino acid protein which is also known as the adipose
most abundant gene transcript 1. Reduction in adiponectin
secretion has been found to be associated with the devel-
opment of insulin resistance in animal models of obesity
and lipoatrophy [4]. Injection of adiponectin into nonobese
diabetic mice may lead to an insulin-independent decrease
in glucose levels [17]. Plasma adiponectin concentrations
in patients with both obesity and type 2 diabetes mellitus
were found to be reduced [18, 19]. Adiponectin and thyroid
hormones share some physiological actions as reduction of
body fat by increasing thermogenesis and lipid oxidation.
One animal study had showed a potential inhibitory
eﬀect of T3 on adiponectin mRNA expression on adipose
tissues [20]. However, adiponectin concentrations had also
been found to be associated with FT4 levels in patients with
hypothyroidism [21]. The eﬀect of thyroid hormones on
the adiponectin levels revealed contrary results, which needs
more study to clarify.
From the limited studies on the relationship between
circulating adiponectin levels and thyroid function status,
results have been inconsistent. In human study, hyper-
thyroidism has been associated with similar [22, 23]o r
elevated [24, 25] circulating adiponectin levels compared
with euthyroid subjects. Normalization of hyperthyroidism
withappropriatetherapywasnotaccompaniedbysigniﬁcant
changes in circulating adiponectin levels in one study [22].
Conversely, in another study a signiﬁcant reduction was
found [26]. In addition, this study also demonstrated that
hyperadiponectinemia was associated with levels of TRAb,
pointing to an immunological inﬂuence on adiponectin
metabolism. However, we did not ﬁnd correlation between
TRAb and adiponectin levels in hyperthyroid patients.
Inthepresentstudy,HOMA-IRvaluesandBMI-adjusted
insulin concentrations were decreased after hyperthyroidism
management. In addition, HOMA-IR and insulin levels were
positively correlated with T3 and FT4 levels in patients with
Graves’ disease. These ﬁndings were consistent with the
assumption that hyperthyroidism is associated with higher
insulin resistance. However, we did not observe diﬀerence in
adiponectinconcentrationsamonghyperthyroidandcontrol
patients and also the posttreatment patients. There was no
correlation between serum insulin or HOMA-IR levels and
plasma adiponectin concentrations. These observations sug-
gest that insulin resistance associated with hyperthyroidism
is not mediated by a reduction in plasma adiponectin levels.
However, because of the small sample, these results must be
interpreted with caution.
Hyperthyroidismcouldaltertheneurophysiologyoffood
intake regulation which may drive the marked hyperphagia
and craving for carbohydrates [27]. The carbohydrate-rich
diet with a high glycemic load appears to be associated
with lower adiponectin concentrations [28]. Therefore, the
carbohydrates intake in hyperthyroid patients may inﬂuence
adiponectin levels.4 Journal of Thyroid Research
Hyperthyroidism is associated with insulin resistance.
However, hyperthyroidism also reduces BMI, which may
increase insulin sensitivity. Plasma adiponectin concentra-
tions were decreased in patients with obesity. Besides, the
levels also paradoxically decreased in an insulin-resistance
state. The concentrations of adiponectin among hyperthy-
roid subjects may be inﬂuenced by many conﬂicting factors.
However, no study has reported a decreased adiponectin
concentration in hyperthyroidism. Therefore, the insulin
resistance associated with thyrotoxicosis is likely not to be
mediated by altered adiponectin secretion.
5. Conclusions
In conclusion, insulin resistance associated with hyperthy-
roidism is not mediated by the levels of plasma adiponectin.
Additional studies are needed to clarify the contribution of
theseadipocytokinesinthedevelopmentofinsulinresistance
in patients with hyperthyroidism.
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